title: Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.
abstract: Reduced-intensity conditioning (RIC) allo-SCT is a potentially curative treatment approach for patients with relapsed Hodgkin's or non-Hodgkin's lymphoma. In the present study, 37 patients underwent RIC allo-SCT after induction treatment with EPOCH-F(R) using a novel form of dual-agent immunosuppression for GVHD prophylaxis with CsA and sirolimus. With a median follow-up of 28 months among survivors, the probability for OS at 3 and 5 years was 56%. Treatment-related mortality was 16% at day +100 and 30% after 1 year of transplant. Acute GVHD grades II-IV developed in 38% of patients, suggesting that the regimen consisting of CsA and an ultra-short course of sirolimus is effective in the prevention of acute GVHD.
authors.affiliation: Department of Hematology, Oslo University Hospital, Oslo, Norway. yngvar.floisand@oslo-universitetssykehus.no
authors.forename: Y
authors.initials: Y
authors.lastname: Fløisand
authors.forename: L
authors.initials: L
authors.lastname: Brinch
authors.forename: T
authors.initials: T
authors.lastname: Gedde-Dahl
authors.forename: G E
authors.initials: GE
authors.lastname: Tjønnfjord
authors.forename: I
authors.initials: I
authors.lastname: Dybedal
authors.forename: H
authors.initials: H
authors.lastname: Holte
authors.forename: D
authors.initials: D
authors.lastname: Heldal
authors.forename: D
authors.initials: D
authors.lastname: Torfoss
authors.forename: E
authors.initials: E
authors.lastname: Aurlien
authors.forename: G F
authors.initials: GF
authors.lastname: Lauritzsen
authors.forename: A
authors.initials: A
authors.lastname: Fosså
authors.forename: G
authors.initials: G
authors.lastname: Lehne
authors.forename: E
authors.initials: E
authors.lastname: Baggerød
authors.forename: G
authors.initials: G
authors.lastname: Kvalheim
authors.forename: T
authors.initials: T
authors.lastname: Egeland
authors.forename: M R
authors.initials: MR
authors.lastname: Bishop
authors.forename: D H
authors.initials: DH
authors.lastname: Fowler
authors.forename: A
authors.initials: A
authors.lastname: Kolstad
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006689:Hodgkin Disease / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D000069283:Rituximab; D020123:Sirolimus / Q000008:administration & dosage*; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D000069283:Rituximab; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D014740:Vidarabine; C024352:fludarabine; D020123:Sirolimus